Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “TEVA PHARMACEUTICAL INDUSTRIES, LTD.”

302 pharma patents match "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 302
Index total 30,257
Page 3 / 13

Quick answer

This filtered view shows 302 pharmaceutical patents matching "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

302 results for “TEVA PHARMACEUTICAL INDUSTRIES, LTD.” · 30,257 patents in full index Clear search

  1. US 8742129

    Crystalline forms of febuxostat

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 3, 2014 · Expires May 29, 2034

    granted
  2. US 8722722

    Raltegravir salts and crystalline forms thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 13, 2014 · Expires May 8, 2034

    granted
  3. US 8709433

    Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 29, 2014 · Expires Apr 24, 2034

    granted
  4. US 8691872

    Dispersions of rasagiline citrate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 8, 2014 · Expires Apr 3, 2034

    granted
  5. US 8673322

    Crystals of laquinimod sodium, and process for the manufacture thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 18, 2014 · Expires Mar 13, 2034

    granted
  6. US 8663703

    Drug microparticles, processes of preparing them and a drug delivery vehicle comprising them

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 4, 2014 · Expires Feb 27, 2034

    granted
  7. US 8653060

    Formulations of 6-mercaptopurine

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Feb 18, 2014 · Expires Feb 13, 2034

    granted
  8. US 8647646

    Crystals of laquinimod sodium, and process for the manufacture thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Feb 11, 2014 · Expires Feb 6, 2034

    granted
  9. US 8614252

    Crystalline solid rasagiline base

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 24, 2013 · Expires Dec 19, 2033

    granted
  10. US 8597666

    Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted
  11. US 8598203

    Treatment of Crohn's disease with laquinimod

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 3, 2013 · Expires Nov 28, 2033

    granted
  12. US 8592442

    Nilotinib HCl crystalline forms

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 26, 2013 · Expires Nov 21, 2033

    granted
  13. US 8580819

    Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 12, 2013 · Expires Nov 7, 2033

    granted
  14. US 8569379

    Use of rasagiline for the treatment of olfactory dysfunction

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 29, 2013 · Expires Oct 24, 2033

    granted
  15. US 8545885

    Stable laquinimod preparations

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 1, 2013 · Expires Sep 26, 2033

    granted
  16. US 8541373

    BChE albumin fusions for the treatment of cocaine abuse

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Sep 24, 2013 · Expires Sep 19, 2033

    granted
  17. US 8536149

    TRPM-2 antisense therapy

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Sep 17, 2013 · Expires Sep 12, 2033

    granted
  18. US 8501766

    Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Aug 6, 2013 · Expires Aug 1, 2033

    granted
  19. US 8487097

    Reference standard for characterization of rosuvastatin

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jul 16, 2013 · Expires Jul 11, 2033

    granted
  20. US 8470344

    Aqueous dispersions and solutions of difficult to dissolve materials and methods of their preparation

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 25, 2013 · Expires Jun 20, 2033

    granted
  21. US 8414918

    Stable imatinib compositions

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted
  22. US 8415314

    Methods for treating multiple sclerosis using antisense oligonucleotides

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted
  23. US 8414920

    Pharmaceutical composition containing irbesartan

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted
  24. US 8410288

    Polymorphs of Saxagliptin hydrochloride and processes for preparing them

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 2, 2013 · Expires Mar 28, 2033

    granted